In 265 patients operated for breast carcinoma the monoclonal antibody serum test CA 15.3 was predictive of metastatic diffusion of the disease. Its level increased in cases of distant metastasis with no significant difference between multiple and single sites (p = 0.014). The concentration of the marker was higher in 21 (23.8%) patients without nodal involvement and in 19 (27.5%) with nodal involvement (p = 0.193). Our study suggests that CA 15.3 may be an aid in the follow-up of patients with metastatic diffusion of breast cancer.
TorneyD.C., WaalkesT.P., AhmannD.Biological markers in breast carcinoma. Incidence of abnormalities of CEA, hCG, three polyamines and three minor nucleosides. Cancer1975; 35: 1095–8.
2.
OgawaT., IzuoM., MoritaH.Evaluation of tumour associated antigen CA 15.3 in the sera of patients with breast cancer. Gan No Rinsho1986; 32: 27–31.
3.
ThorA., WeekoM.O., SchlomJ.Monoclonal antibodies and cancer. Seminars in Oncology1986; 13: 4, 393–401.
4.
BeardD.B., HeskellC.CEA in breast cancer. Am J Med1986; 80: 241–5.
5.
GionM., MioneR., DittadiR., GriggioL.CEA, ferritin, TPA, and CA 15.3 in breast cancer: Relationship between carcinoma and normal breast tissue. Int J Biol Markers1986; 1, 1: 33–8.
6.
KufeD., InghiramiG.Abe differential reactivity of a novel monoclonal antibody (DF3) with malignant versus benign breast tumours. Hybridoma1984; 3: 223–6.
7.
HilkensJ., BuijsF., HilgersJ.Monoclonal antibodies against human milk fat globule membranes detecting differentiation antigen of the mammary gland and its tumours. Int J Cancer1984; 34: 197–201.
8.
Pons-AnicetD.M.F., KrebsB.P., MiraR., NamerM.Value of CA 15.3 in the follow-up of breast cancer patients. Br J Cancer1987; 55: 567–9.
9.
BatesB.E., LongoD.L.Use of serum markers in cancer diagnosis and management. Seminars in Oncology1987; 14, 2: 102–38.
10.
GangY., AdachiI., OkhuraH., YamamotoH., MizuguchiY., AbeK.CA 15.3 is present as a novel marker in the sera of patients with breast cancer and other malignancies. Gan To Kagaku Ryoho1985; 12: 2379–81.
11.
BallestaA.M., MolinaR., MarinJ.L.A new tumor marker CA 15.3 defined by monoclonal antibodies. Initial clinical evaluation in patients with breast cancer. Proc. XIII Annual Meeting ISOBM, Paris. 1985.
12.
TobiasR., RothwellC., WagnerJ., GreenA., LiuY.S.VDevelopment and evaluation of radioimmunoassay for the detection of monoclonal antibody defined breast tumor associated antigen 115D8/DF3. Clin Chem1985; 31: 986–90.
13.
HayesD.F., ZurawskiV.R., KufeD.W.Comparison of circulating CA 15.3 and CEA levels in patients with breast cancer. J Clin Oncol1986; 4: 1542–50.
14.
SacksN.P.M., StarkerS.A., ThompsonC.H.Comparison of mammary serum antigen (MSA) and CA 15.3 levels in the serum of patients with breast cancer. Br J Cancer1987; 56: 820–4.
15.
MaigreM., FumoleauP., RicolleauG.Le CA 15.3 dans le cancer du sein. Comparaison avec l'ACE. Sem Hop Paris1988; 64, 1: 9–13.
16.
ThirionB., BarretB.Results of a multicentric study with CA 15.3 new tumor marker for breast cancer (poster). Symposium CIS. Paris, Jan. 1987.
17.
WangD.Y., BulbrookR.D., HaywardJ.L., HendrickJ.C., FranchimontP.Relationship between plasma carcinoembryonic antigen and prognosis in women with breast cancer. Eur J Cancer1975; 11: 615–9.
18.
BollaM., DaidjH., LachetB., BouchetY., VrousosC.L'antigen carinoembryonnaire dans les tumeurs du sein: Evaluation initiale et surveillance. Bull Cancer1983; 70: 300–5.
19.
NamerM., KrebsB.P., RameauP., HeryM., PhilipC.Les marqueurs tumoraux dans le cancer du sein: comment les utiliser en 1985? In: Demaille, ed. Les maladies du sein: formation medicale continue en sénologie. 7ème journée de la Société Francaise de Sénologie et Phatologie Mammaire, 1985; 20.
